BCR and prostate cancer: We addressed this uncertainty and hypothesized that prostate cancer patients with an interval from biopsy to RP >3 and ≤6 months do not differ from those with an interval from biopsy to RP ≤3 months regarding histopathological outcomes at RP as well as BCR rates after RP.